The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
MPN Workshop of the Carolinas 2024 | Investigating CHIP to address the unanswered questions that remain
David Steensma, MD, Ajax Therapeutics, New York, NY, discusses clonal hematopoiesis of indeterminate potential (CHIP), a precursor condition that can progress to various hematological malignancies, including myeloproliferative neoplasms (MPNs). At present, tools do not exist to identify patients who are at high risk of progression to malignancy, and progress is needed in this area to allow for early intervention in high-risk individuals. This interview took place at the 1st Annual MPN Workshop of the Carolinas in Asheville, NC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Employment: Ajax Therapeutics.
